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MicrotubulesThe role of caveolin-2 (cav-2), independently of caveolin-1 (cav-1) and caveolae, has remained elusive. Our
data show that cav-2 exists in the plasma membrane (PM) in cells lacking cav-1 and forms homo-oligomeric
complexes. Cav-2 did not interact with cavin-1 and cavin-2 in the PM. Rab6-GTP was required for the
microtubule-dependent exocytic transport of cav-2 from the Golgi to the PM independently of cav-1. The
cav-2-oligomerized noncaveolar microdomain was unaffected by cholesterol depletion and protected from
shearing of silica-coated PM. Activation of insulin receptor (IR) was processed in the microdomain. Actin
depolymerization affected the formation and sustenance of cav-2-oligomerized noncaveolar microdomain
and attenuated IR recruitment to the microdomain thereby inhibiting IR signaling activation. Cav-2 shRNA
stable cells and the cells ectopically expressing an oligomerization domain truncation mutant, cav-2Δ47–86
exhibited retardation of IR signaling activation via the noncaveolar microdomain. Elevation in status of
cav-2 expression rendered the noncaveolar activation of IR signaling in cav-1 down-regulated or/and
cholesterol-depleted cells. Our ﬁndings reveal a novel homo-oligomeric cav-2 microdomain responsible for
regulating activation of IR signaling in the PM.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Lipid rafts are ﬂuctuating nanoscale domains assembled with
cholesterol, sphingolipid, and proteins that can be stabilized into plat-
forms and function in membrane signaling and trafﬁcking [1–3].
Caveolae are cav-1-enriched invaginations of the PM that represent a
subdomain of the lipid rafts [4]. Cholesterol is required for the caveolae
formation and maintenance [5,6]. Caveolae localization of neutral
glycolipids and sphingomyelin has been shown [7,8]. Ganglioside
GM1 and GM3 were enriched at lesser extent in caveolae, but also
present outside caveolae [9]. GM3-enriched microdomain had different
lipid composition from caveolin-enriched microdomain and was not
affected by cholesterol-sequestering drugs [9,10]. Thus, these reports
suggest that caveolae and sphingolipid-enriched microdomain can
exist independently and that speciﬁc sphingolipids and cholesterol
dependency might partition differentially between caveolae and
other noncaveolar microdomains.
Although cav-1 is an essential component of caveolae, cav-1 is
expressed in neurons and leukocytes lacking caveolae, and caveolins
can be found outside of caveolae even in cells with caveolae [11–13].R, insulin receptor; PM, plasma
rane; LLDM, light low-density
vesicle; LDMV, low density
, methyl-β-cyclodextrin; CCD,
tor
82 557599363.
l rights reserved.Cav-2 in the Golgi targets to caveolae upon formation of hetero-
oligomers with cav-1 [14,15] but cav-2 is not essential for caveolae
formation [16–18]. Homo-oligomeric cav-1 domain in the PM, distinct
from caveolae has been reported [19]. Thus numerous studies have
attempted to characterize heterogeneous distribution of lipids and
proteins between caveolae and noncaveolar microdomains. Neverthe-
less, speciﬁcity for transmembrane signal activation through PM
microdomains is restricted to caveolae because of lack of visibility as
morphological structures and information for the dynamic formation
of the noncaveolar microdomains.
Our investigation of cav-2 regulation of insulin signaling, indepen-
dently of cav-1 and caveolae, in cells lacking cav-1 and cav-2-expressed
cells having no endogenous caveolins showed that cav-2 interacts with
IR and activates IR signaling [20–24]. Although cav-2 targeting to
caveolae in PM was known to depend on cav-1 [14,15,18,25–27], our
studies using subcellular fractionation and PM sheet assay indicated
that cav-2 localizes in the PM in the absence of cav-1. The cav-2 locali-
zation was unaffected by cholesterol depletion and its level was not
changed in response to insulin [28]. Further, our studies demonstrated
that cav-2 but not cav-1 translocates to the nucleus speciﬁcally in re-
sponse to insulin [20–24,28]. Our investigation on subcellular distribu-
tion of cav-2 and cav-2 pool responsible for the nuclear targeting
showed that cav-2 in the Golgi, but not PM is transported to the inner
nuclearmembrane in response to insulin [28]. Thus the ﬁndings suggest
that cav-2 pool in the PM is distinct from those in the Golgi and nucleus
and might have different physiochemical property and function
irrespectively of cav-1. However, even though cav-2would presumably
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of PM targeting of cav-2 and its functional signiﬁcance in the PM have
not been explored.
Here, we report that a novel actin cytoskeleton-dependent cav-2-
enriched noncaveolar microdomain regulates IR signaling in the PM.
Further, our data demonstrate that elevation of cav-2 expression
status relative to cav-1 leads to reconstitution of the noncaveolar
microdomain for activation of IR signaling in caveolae-depleted cells.2. Materials and methods
2.1. Materials
Antibodies and reagents used were purchased as follows: anti-
cav-2 (BD 610685), anti-cav-1 (BD 610406), anti-ﬂotillin-1 (BD
610820), anti-ERK1 (BD 610031), anti-Akt (BD 610860), anti-
phosphotyrosine-PY20 (BD 610000), and E-cadherin (BD 610182)
antibodies from BD Transduction Laboratories; anti-GM130
(ab31561) antibody from Abcam; anti-calnexin (sc-11397), anti-IR
(sc-711), anti-cav-2 (sc-7942), and anti-actin (sc-1616) antibodies
from Santa Cruz Biotechnology; anti-GFP (#2555), anti-p-ERK
(#9101), and anti-p-Akt (#9271) antibodies form Cell Signaling;
anti-FLAG® M2 (F 1804), anti-rabbit IgG-peroxidase (A 6154), and
anti-mouse IgG-peroxidase conjugate (A 4416) antibodies from
Sigma-Aldrich; anti-transferrin receptor (TfR) (13-6800) antibody
from Invitrogen; cholera toxin B subunit (CTB)-Alexa Fluor® 594
conjugates (C-34777) from Molecular Probes; human insulin
from Eli Lilly; colchicine (C3915), methyl-β-cyclodextrin (MβCD)
(C4555), cytochalasin D (CCD) (C8273), and 4′-6-Diamidino-2-
phenylindole (DAPI) (D8417) from Sigma-Aldrich; U18666A
(662015) and latrunculin B (LatB) (428020) from Calbiochem.2.2. Cell culture
Hirc-B cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) (Gibco/BRL, Grand Island, NY) containing 5 mM
D-glucose supplemented with 10% (v/v) fetal bovine serum (FBS)
(Sigma, St. Louis, MO), 100 nM methotrexate (Sigma, St. Louis, MO),
and 0.5% gentamycin (Gibco/BRL, Grand Island, NY) in a 5% CO2 incu-
bator at 37 °C. HEK293T and 3T3L1 cells were grown in DMEM
containing 5 mM D-glucose supplemented with 10% (v/v) FBS and
0.5% penicillin/streptomycin (Sigma, St. Louis, MO) in a 5% CO2 incu-
bator at 37 °C.2.3. Plasmids
A full-length cav-2 (GenBank Accession No. NM_131914) [21–24,
28], Rab6 (NM_002869) [28], cavin-1 (NM_012232.5), cavin-2 (NM_
004657.5), or ﬂotillin-1 (NM_005803) cDNA was subcloned into
pcDNA3 vector (Invitrogen, Carlsbad, CA). The resulting entry vector
of cav-2, cavin-1, cavin-2, or ﬂotillin-1 was converted into self-
constructed GFP tagging destination expression vector (pEGFP-N1 vec-
tor, Clontech Laboratories). IR (NM_10051.1) plasmid (Gateway PLUS
shuttle clone for INSR, GC-Y2826-CF) was obtained from Genecopoeia.
For construction of a vector expressing mCherry or FLAG-tagged cav-2
or GFP-tagged IR, cav-2 or IR was subcloned into the pDonor207 and
then moved into the pDEST-N-RFP, pDS_FLAG-XB or pDS_GFP-XB
vector using GatewayTM Technology (Invitrogen). DsRed-Monomer
was replaced with mCherry in order to improve ﬂuorescence intensity.
FLAG-cav-2Δ47–86 mutant was generated by using FLAG-cav-2 as
template via EZchange site-directed mutagenesis kit (Enzynomics,
Daejeon, Korea). A construct encoding T27N-Rab6 was generated by
PCR mutagenesis using mutated oligonucleotides as described [28].
All expression vectors were veriﬁed by sequencing.2.4. Reverse transcription-PCR
Total RNAwas extracted fromHirc-B and HEK293T cells with TRIzole
reagent (SolGent Co., Ltd.). cDNAwas generated using reverse transcrip-
tion kit (Bioneer). The cDNAwas used as the template for the subsequent
PCR ampliﬁcation. PCR primers were for glyceraldehydes-3-phosphate
dehydrogenase (GAPDH); 5´-ACCACCATGGAGAAGGCTGG-3´ and 5´-CT
CAGTGTAGCCCAGGATGCC-3´, cav-2 (rat); 5´-ATGGGGCTGGAGACTGA
GAAG-3´ and 5´-TCAGTCATGGCTCAGTTGCATG-3´, cav-2 (human); 5´-
ATGGGGCTGGAGACGGAG-3´ and 5´-TCAATCCTGGCTCAGTTGCA-3´,
cav-1 (rat); 5´-ATGTCTGGGGGTAAATACGTA-3´ and 5´-TCATATCTCTTT
CTGCGTGCT-3´, cav-1 (human); 5´-ATGTCCACGGGCGGAGACTTC-3´ and
5´-TTATATTTCTTTCTGCAAGTTGATGCG-3´. PCR was performed using
AccuPower PCR PreMix kit (Bioneer). The PCR fragments were separated
by running on 1% agarose gels.
2.5. Ablation of endogenous cav-2 by shRNA
To establish stable cell lines that express a cav-2 short-hairpin RNA
(shRNA), a cav-2 speciﬁc shRNA lentiviral plasmid set (MISSION®shRNA
Bacterial Glycerol Stock) and the MISSION® Non-Target shRNA Control
Vector (pLKO.1-puro) were purchased from Sigma. For stable transfec-
tion, Hirc-B cells were transfected with cav-2 shRNA expressing plasmid.
After 48 h incubation, 1 μg/ml puromycin (Clontech, USA) was added to
the cultures to select for puromycin-resistant clones. One week later, in-
dependent colonies were picked using cloning cylinder (Sigma, St. Louis,
MO), subcultured, and tested for cav-2 expression by RT-PCR and immu-
noblot analysis. Stable cell lines that express a cav-2 shRNA were then
selected.
2.6. Silencing of Rab6, cav-1 and cav-2 by siRNA
siRNA targets of Rab6, cav-1, cav-2, and scramble control were pur-
chased from Bioneer Corp. (Daejon, Korea) and Dharmacon Research,
Inc., respectively. The siRNA oligonucleotideswere synthesized to the fol-
lowing target sequences: Rab6; sense (5´-AGGCAGAUCAGGUAAAGCA-3´)
and antisense (5´-UGCUUUACCUGAUCUGCCU-3´), cav-1; sense (5´-CAG
UUGUACCAUGCAUUAA-3´) and antisense (5´-UUAAUGCAUGGUACAAC
UG-3´), cav-2; sense (5´-GUAAAGACCUGCCUAAUGGUU-3´) and antisense
(5´-PCCAUUAGGCAGGUCUUUACUU-3´, scramble control; 5´-GGAAAGA
CUGUUCCAAAAA-3´. Transfection of the siRNA duplexes was carried out
using DharmaFECT Transfection Reagents (Dharmacon) for 48 h.
2.7. Confocal microscopy
Hirc-B cells were ﬁxed with 3.7% paraformaldehyde in phosphate-
buffered saline (PBS) for 20 min, and permeabilized with 0.1% Triton
X-100 in PBS for 20 min. Permeabilized cells were rinsed with PBS
and blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at
room temperature (RT). Cells were rinsed with PBS and incubated
with anti-cav-2 and anti-IR antibodies in 1% BSA in PBS for overnight
at 4 °C. After washing three times with PBS, the cav-2 and anti-IR an-
tibodies were detected with TRITC- and FITC-conjugated anti-mouse
and anti-rabbit secondary antibodies, respectively in 1% BSA in PBS
for 2 h at RT. The coverslips were washed and mounted on glass
slides. Fluorescent images were obtained using an Olympus Fluoview
1000 confocal microscope attached to an Olympus BX61 vertical
microscope equipped with PlanApo 60×/1.40 oil immersion objective
(Olympus). Quantitation of colocalization of cav-2 with IR was
performed with the Line Proﬁle Tool of Image-ProPlus 6.1 (Media
Cybernetics). To analyze colocalization of cav-2 with cavin-1 or
cavin-2, cavin-1-GFP or cavin-2-GFP transfected Hirc-B cells were
subjected to confocal microscopy analysis using anti-cav-2 primary
and anti-TRITC-conjugated anti-mouse secondary antibodies as
above.
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Subcellular fractionation was carried out to generate the fractions
that are enriched in markers of the PM, ER (high density microsomes,
HDM), and Golgi (low density microsomes, LDM) as described previ-
ously [29,30]. Brieﬂy, cells were washed with ice-cold PBS and scraped
into isotonic buffer containing 250 mM sucrose, 20 mM Tris–HCl,
1 mM EDTA, 15 mM KCl, 2 mM MgCl2, 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF), 1 mM sodium orthovanadate, 1 μg/μl aprotinin, and
1 μg/μl leupeptin. Cell lysates were homogenized using 10 strokes of
a Dounce homogenizer and centrifuged at 10,000 ×g for 45 min at
4 °C. The membrane pellet was resuspended in the isotonic buffer.
The PM was isolated by loading the resuspended membrane pellet
onto a 1.12 M sucrose cushion and centrifuging at 100,000 ×g for 2 h
at 4 °C in a SW41Ti rotor (Beckman Instruments). The PM fraction at
the interface was collected, diluted with ice-cold PBS and pelleted by
centrifugation at 200,000 ×g for 1 h at 4 °C in a SW41Ti rotor. The
initial supernatant was centrifuged at 48,000 ×g for 20 min at 4 °C in
TLA-100.3 rotor (Beckman Instruments), yielding a pellet of HDM.
The supernatant was then recentrifuged at 212,000 ×g for 70 min at
4 °C in TLA-100.3 rotor, yielding a pellet of LDM.
2.9. Cell surface biotinylation assay
Cell surface proteins were biotinylated with the membrane-
impermeant reagent sulfo-NHS-LC-biotin (0.5 mg/ml) in PBS containing
0.1 mM CaCl2 and 1 mM MgCl2 for 45 min at 4 °C. Cells were washed
with ice-cold PBS and lysed with lysis buffer (50 mM Tris–HCl, 1 mM
EDTA, 150 mMNaCl, 10% glycerol, 1% Nonidet P-40, and protease inhib-
itor, pH 7.4). Biotinylated proteins were precipitated with NeutrAvidin
agarose bead (Pierce) for 2 h at 4 °C while shaking. The immuno-
complexes were collected by centrifugation at 12,000 rpm for 10 min
at 4 °C and washed twice with lysis buffer and twice with PBS. After
the ﬁnal wash the pellet was resuspended in 30 μl of 2× SDS-PAGE
sample buffer. The immunoprecipitates were then resolved, separated
by SDS-PAGE, and subjected to immunoblot analysis.
2.10. PM sheet assay
PM sheet assay was performed as described previously [28]. Brief-
ly, cav-2-GFP-transfected Hirc-B cells were incubated on ice with
0.5 mg/ml of poly-L-lysine in PBS for 30 s and washed with ice-cold
hypotonic buffer (23 mM KCl, 10 mM Hepes, pH 7.5, 2 mM MgCl2,
and 1 mM EGTA). The cells were sonicated for 3 s (Sonics Vibra Cell
Sonicator, set at 10% amplitude) in ice-cold sonication buffer
(70 mM KCl, 30 mM Hepes, pH 7.5, 5 mM MgCl2, 3 mM EGTA,
1 mM DTT, and 0.1 mM PMSF) and used for confocal microscopy
analysis. To assess colocalization of cav-2-GFP with endogenous IR
or cav-2 and cav-2 with TfR or ﬂotillin-1, PM sheet images were ana-
lyzed using Intensity Correlation Analysis Plugin of the Image J [31].
The distribution of the intensity value for each pixel of a channel is
plotted against the product of the difference of the mean (PDM)
of the two channels. The PDM value is expressed as “PDM = (green
intensity − mean green intensity) × (red intensity − mean red
intensity)”. The PDM image where each pixel is equal to the PDM
value at that location is pseudocolored in yellow and the areas in
blue represent the areas of positive and negative PDM values, corre-
sponding to the presence and absence of colocalization, respectively.Fig. 1. Cav-2 colocalizes with IR in the PM. (A) Hirc-B cells were labeled with anti-cav-2 and
using DAPI. HEK293T cells were cotransfected with cav-2-mCherry and IR-GFP. Scale ba
coampliﬁed as the internal control. (r, rat; h, human) (C) Hirc-B cells were processed fo
gold-labeled cav-2 in the PM. Right panel shows a representative electron microscope
M, mitochondria) Scale bars, 0.2 μm. (D) Hirc-B and cav-2-transfected HEK293T cells wer
and detected with antibodies speciﬁc for E-cadherin, calnexin and GM130 as makers f
HEK293T cells were labeled with sulfo-NHS-LC-biotin and cell surface biotinylation was a
TfR in the PM sheets derived from Hirc-B cells is shown in Merge and PDM values. (yellow2.11. Electron microscopy
For immunoelectron microscopy, Hirc-B cells were rinsed and in-
cubated at 37 °C in Ringer's solution for 15 min before being ﬁxed
in Ringer's solution containing 2% paraformaldehyde and 0.2% glutar-
aldehyde for 30 min at 37 °C. The ﬁxed cells were rinsed in PBS,
scraped and collected by centrifugation. The cell pellet was postﬁxed
for 30 min with 1% osmium tetroxide (OSO4) in PBS containing 1.5%
potassium ferrocyanide (reduced osmium), dehydrated, and embed-
ded in LR-White resin as previously described [32]. Ultrathin sections
mounted on formvar-coated nickel grids were blocked with 3% BSA in
PBS for 30 min, and then incubated with anti-cav-2 antibody for 1 h
followed by 18 nm gold-conjugated goat anti-rabbit antibody
(Jackson Immuno Research Laboratories, Inc.) for 1 h. The sections
were then stained with 2% uranyl acetate and examined in a Tecnal
12 transmission electron microscope (FEI Co., Hillsboro, OR). For elec-
tron microscopy, cells were ﬁxed with 2.5% glutaraldehyde for 2 h,
postﬁxed with 1% OSO4 for 2 h, dehydrated, and embedded in
LR-White resin. Ultrathin sections were placed on copper grids,
poststained with 2% (w/v) aqueous uranyl acetate and lead citrate,
and then observed by electron microscope.
2.12. Velocity gradient centrifugation
Sucrose velocity gradient centrifugation was performed as de-
scribed previously [33,34]. 3T3L1 and Hirc-B cells were lysed in 0.5,
1 or 2% TX-100, or in 60 or 120 mM n-octylglucoside (OG) lysis buffer
(100 mM NaCl, 20 mM Tris–HCl, pH 7.4, 5 mM EDTA, and protease
inhibitors) for 20 min at RT. The lysates were centrifugated at
1100 ×g for 5 min. The supernatant was loaded onto 10–40% linear
sucrose gradients containing 0.5, 1 or 2% TX-100, or in 60 or
120 mM OG lysis buffer. After centrifugation in a SW41Ti rotor at
237,020 ×g for 255 min at 4 °C, fourteen 720 μl fractions were
collected from the top to the bottom. An equal volume from each
gradient fraction was separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) and subjected to immunoblot analysis.
2.13. Quantitation of cholesterol
Cholesterol was measured by using an Amplex® Red Cholesterol
Assay Kit (Molecular Probes, A12216) according to the manufacturer's
protocols.
2.14. Isolation of low-density membrane vesicle (LDMV) from
silica-coated PM
Isolation of PM using cationic silica (LUDOX® CL colloidal silica
(Sigma-Aldrich, 420883)) was performed as described previously
[35]. 3T3L1, Hirc-B, and HEK293T cells were washed with ice-cold
PBS and scraped into 2 ml PM coating buffer (PMCB: 20 mM MES,
150 mM NaCl, and 800 mM sorbitol, pH 5.3) and placed into a 5 ml
10% suspension of cationic colloidal silica in PMCB drop by drop.
The solution was shaken gently at 4 °C for 15 min and added with
20 ml PMCB, and centrifuged at 900 ×g for 5 min at 4 °C. The pellet
was washed with 20 ml PMCB and centrifuged at 900 ×g for 5 min
at 4 °C to remove any excess silica. The cells were suspended in
2 ml PMCB and placed dropwise into a buffer of 10 mg/ml
polyacrylicacid in PMCB. The solution was rocked and centrifuged atanti-IR antibodies followed by TRITC- and FITC-conjugated antibodies. DNA was stained
r, 20 μm. (B) Cav-1 and cav-2 mRNA levels were analyzed by RT-PCR. GAPDH was
r immunogold staining. Arrows in the left and middle panels indicate localization of
exhibiting the absence of caveolae. (PM, plasma membrane; G, Golgi; N, nucleus;
e fractionated and analyzed by immunoblotting using antibodies against cav-2, or IR
or the PM, HDM (ER) and LDM (Golgi) fractions. (E) Hirc-B and cav-2-transfected
ssayed. (F) Colocalization of cav-2-GFP with endogenous IR or cav-2 and cav-2 with
, positive PDM; blue, negative PDM) Scale bars, 20 μm.
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hypotonic lysis buffer (2.5 mM imidazole, pH 7.0, and 1 mM PMSF)
on ice for 30 min with interval vortex, and was broken with 50
strokes by a tight-ﬁtting Dounce homogenizer. The lysates were
centrifuged at 900 ×g for 20 min at 4 °C. The pellet including the nu-
clei and silica-coated PM was resuspended in 10% sucrose solution.
Four ml of 69% sucrose was placed at the bottom of an ultracentrifuge
tube and a discontinuous sucrose gradient was generated by layering
4 ml of 54% sucrose, and then 4 ml of the 10% sucrose solution includ-
ing nuclei and silica-coated PM. Gradients were centrifuged at
30,000 ×g for 2 h at 4 °C in a SW41Ti rotor. The cationic
silica-coated PM fraction at the bottom of the tube was resuspended
in hypotonic lysis buffer and centrifuged at 30,000 ×g for 20 min at
4 °C in a SW41Ti rotor. LDMVs were separated from the
silica-coated PM by sonication and then LDMV fractions were isolated
by ultracentrifugation in the discontinuous sucrose gradient system
as described [36].
2.15. Extraction of lipid microdomains from PM fractions
To separate HLDM from LLDM in the PM, the puriﬁed PM fractions
from the subcellular fractionation as described above were subjected
to a four-step sucrose density gradient fractionation as described
[37,38]. Brieﬂy, puriﬁed PM was resuspended with 2 ml of 500 mM so-
dium carbonate, pH 11.0 and homogenized using 10 strokes of a Dounce
homogenizer, and mixed with 2 ml of 90% sucrose in Mes-buffered sa-
line (MBS: 25 mM MES, 150 mM NaCl, pH 6.5). The extraction mixture
was placed at the bottom of an ultracentrifuge tube and overlaid with
3 ml of 35% sucrose, 4 ml of 21% sucrose, and 1 ml of 5% sucrose in
MBS containing 250 mM sodium carbonate. Gradients were centrifuged
at 280,000 ×g for 18 h at 4 °C in a SW41Ti rotor. From the top of each
gradient, 0.5 ml gradient fractions were collected to yield a total of 24
fractions. An equal volume from each gradient fraction was separated
by SDS-PAGE and subjected to immunoblot analysis.
2.16. Giant plasma membrane vesicle (GPMV) isolation
Isolation of GPMVs was performed as described [39]. Brieﬂy,
Hirc-B cells were grown to conﬂuency in a 25 cm2 tissue culture
ﬂask and co-transfected with cav-2-mCherry and ﬂotillin-1-GFP.
Cells were then treated with or without 10 mM MβCD for 2 h, 1 μM
CCD for 15 min, or 1 μM LatB for 30 min. Cells were washed twice
with GPMV buffer (2 mM CaCl2, 10 mM Hepes, and 0.15 M NaCl,
pH 7.4), and ~1.5 ml of freshly prepared GPMV reagent was added,
consisting of 2 mM N-ethylmaleimide in GPMV buffer. The ﬂasks
were incubated for 1 h at 37 °C while slowly shaking at 60 rpm.
After incubation, GPMVs that had detached from the cells were gently
decanted into a conical tube. The tube was allowed GPMVs to settle
on ice for 45 min and the GPMVs were collected by removing ~20%
of the total volume from the bottom of the tube. For making micros-
copy samples, a chamber was created by a square of vacuum grease
(Dow Corning) on a coverslip, into the middle of which 20 μl of
GPMV suspension was deposited, followed by sealing of the chamber
with another coverslip. The ﬂuorescence of the GPMVs was visualized
using a confocal microscope system (BX-61; Olympus) equipped with
a PlanApo 100×/1.35 oil immersion objective lens (Olympus). For mi-
croscopic analysis of cav-2 localization in ganglioside-enriched LLDM,
GPMVs were incubated with 2 μg/ml of CTB-Alexa Fluor® 594 conju-
gates for 30 min at 4 °C before makingmicroscopy samples. Measure-
ment of colocalization of cav-2-GFP with CTB-Alexa Fluor® 594
conjugates or cav-2-mCherry with ﬂotillin-1-GFP was performed by
the Colocalization Finder Plugin of Image J as described previously
[24,28]. The amount of colocalization of cav-2-GFP with CTB-Alexa
Fluor® 594 conjugates or cav-2-mCherry with ﬂotillin-1-GFP was cal-
culated as the number of colocalized pixels with threshold pixels in
the CTB-Alexa Fluor® 594 conjugates or ﬂotillin-1-GFP. Averagesand standard errors were computed over ﬁve images per condition
for a minimum of twenty GPMVs per condition (n = 3).
2.17. Dot blot
For analysis of ganglioside GM1, equal volume of the fractionated
samples from the four-step sucrose density gradient fractionation of
the PM as described above was dot-blotted onto Hybond-C extra
nitrocellulose membranes (Amersham Pharmacia Biotech). The
membranes were blocked with 5% (v/v) nonfat dry milk in TBS, 0.1%
(v/v) Tween 20 and incubated with HRP-conjugated CTB (Invitrogen,
Molecular Probes, C-34780), a ligand for ganglioside GM1 in the PM,
and then revealed by chemiluminescence.
2.18. Immunoblotting
An equal volume from each gradient fraction was separated by
SDS-PAGE and transferred to a polyvinylidenediﬂuoride membrane
(Millipore). The membrane was blocked overnight at 4 °C with 5%
non-fat dry milk in TBS, 0.1% (v/v) Tween 20 and then incubated
with primary antibody for 2 h at RT. After washed with TBS, 0.1%
(v/v) Tween 20, the membrane was incubated with peroxidase-
conjugated secondary antibody for 1 h at RT. The membrane was
washed with TBS, 0.1% (v/v) Tween 20 and the blot was developed
using the ECL detection reagent (RPN2106, Amersham Biosciences).
2.19. Immunoprecipitation
HEK293T cells were cotransfected with cavin-1-GFP or cavin-2-
GFP and FLAG-cav-2 and subjected to the PM fractionation as de-
scribed above. The puriﬁed PM pellet was resuspended in immuno-
precipitation buffer (1% Triton X-100, 150 mM NaCl, 10 mM
Tris–HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA (pH 8.0), 0.2 mM sodi-
um orthovanadate, 0.2 mM PMSF, and 0.5% Nonidet P-40) containing
60 mM OG and incubated overnight with anti-FLAG antibody at 4 °C.
Then 20 μl of protein G-Agarose (Calbiochem) was added and the
mixture was rotated for 4 h at 4 °C. The immunocomplexes were col-
lected by centrifugation at 12,000 rpm for 10 min at 4 °C and washed
three times with ice-cold immunoprecipitation buffer. After the ﬁnal
wash the pellet was resuspended in 30 μl of 2× SDS-PAGE sample
buffer. The immunoprecipitates were then resolved, separated by
SDS-PAGE, and subjected to immunoblot analysis. For immunoprecip-
itation analysis of IR with cav-2, Hirc-B cells were pretreated with or
without 1 μM CCD for 15 min or 1 μM LatB for 30 min followed by
incubation with or without 100 nM insulin for 10 min, washed
with ice-cold PBS and lysed in the immunoprecipitation buffer
containing 60 mM OG. The lysates were centrifugated at
12,000 rpm for 20 min at 4 °C and the supernatants were subjected
to immunoprecipitation with anti-IR antibody and analyzed as
described above.
2.20. Statistics
Chemiluminescent images of immunoblots were analyzed by
scanning densitometry using a Kodak Gel Logic 100 imaging System
(Eastman Kodak Co., New Haven, CT, USA). Data were analyzed
with Student's t test. Values are given as means ± S.E. P values
of b 0.05 were indicated in ﬁgures. Unless otherwise stated, n refers
to independent experiments, each performed in triplicate.
3. Results
3.1. Cav-2 colocalization with IR in the PM
Being consistent with the intracellular distribution of cav-2 from
our recent report [28], cav-2 localization in the Golgi, ER, inner
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cence microscopy in Hirc-B cells expressing cav-2 without cav-1
and cav-2-transfected HEK293T cells with no detectable endogenous
cav-1 and cav-2 expression (Fig. 1A). No cav-1 expression in the cells
is demonstrated by RT-PCR analysis (Fig. 1B). The localization of cav-2
in the PM (Fig. 1C, Arrows) and Golgi is further demonstrated by
immunoelectronmicroscopy. As we have also previously demonstrat-
ed that cav-2 prolongs IR activation by its interaction with IR [23],
endogenous cav-2 colocalizes with IR in the PM in Hirc-B cells
(Fig. 1A, top panel). And when HEK293T cells were cotransfected
with cav-2-mCherry and IR-GFP, cav-2-mCherry comerged with
IR-GFP in the PM (Fig. 1A, bottom panel). Subcellular fractionation
conﬁrmed the subcellular localization of cav-2 observed by confocal
microscopy (Fig. 1A) and demonstrated that cav-2 is cofractionated
in the PM fraction with IR in Hirc-B cells and cav-2-expressed
HEK293T cells (Fig. 1D). To further verify if cav-2 interacts with IR
in the PM, cell surface biotinylation assay was performed. As shown
in Fig. 1E, cav-2 was in association with the cell surface biotinylated
IR. PM sheet assay with a detailed quantitative colocalization analysis
also conﬁrmed that cav-2 colocalizes with IR in the PM (Fig. 1F, top
panel). This is demonstrated in a false color image (PDM values); yel-
low color represents dependent localization of both factors, whereas
blue color shows segregated localization. The cav-2-GFP comerged
with endogenous cav-2 in the PM sheets (Fig. 1F, middle panel) but
cav-2 did not colocalize with TfR, a non lipid-rafts PM marker protein
(Fig. 1F, bottom panel). Together, these data demonstrate that cav-2
colocalizes with IR in the PM and point out that cav-2 localizes in
the PM independently of cav-1.
3.2. Microtubule-dependent Rab6-GTP-mediated PM targeting of cav-2
Rab6 regulates exocytic transport by enhancing kinesin-driven
movement of secretory vesicle from the Golgi [40]. We have previ-
ously demonstrated that cav-2 speciﬁcally interacts with Rab6 [28].
Thus, we explored whether the PM targeting of cav-2 is regulated
by the Rab6-dependent transport. In the PM sheet derived from
Hirc-B cells, cav-2-GFP colocalized with ﬂotillin-1, a lipid-rafts PM
marker protein (Fig. 2A, top panel). However, cav-2-GFP was not
detected in the PM sheet derived from Rab6-depleted cells indicating
complete inhibition of cav-2 targeting to the PM (Fig. 2A, bottom
panel). When cells were transfected with dominant negative T27N-
Rab6 mutant, endogenous cav-2 targeting to the PM was greatly re-
duced as compared to vector control (Fig. 2B). To further test whether
the translocation of cav-2 to the PM is dependent on microtubule-
based transport, cells were treated with colchicine, a microtubule de-
polymerization agent. In untreated cells, endogenous cav-2 comerged
with ﬂotillin-1 (Fig. 2C, top panel). However, the colocalization was
inhibited in the PM sheet from the colchicine-treated cells (Fig. 2C,
bottom panel). Analysis of PDM values veriﬁed requirement of
Rab6-GTP and microtubules in the PM targeting of cav-2.
3.3. Noncaveolar homo-oligomeric cav-2 microdomain refractory to the
cholesterol depletion in the PM
To examine whether cav-2 exists as oligomerized form, sucrose
velocity gradient centrifugation was performed. Cav-2 formed large
hetero-oligomeric complexes (fractions, 8–11; high MW) with cav-1
(i.e. the 70S oligomers [33]) in 3T3L1 cells (Fig. 3A, a). To assess integ-
rity of the oligomeric complexes, we tested effects of detergents, 60
and 120 mM OG on the solubilization of the complexes prior to
sucrose velocity gradient centrifugation. The hetero-oligomers were
resolved in monomeric and small oligomeric complexes (fractions,
1–4; low MW) (i.e. the 8S oligomers [33]) by 60 and 120 mM OG
treatments. In Hirc-B cells, cav-2 formed large homo-oligomeric com-
plexes (fractions, 8–11; high MW) without cav-1 (Fig. 3A, b). The
homo-oligomers were resolved in monomeric and small oligomericcomplexes (fractions, 1–4; low MW) by 2% TX-100 and 60 and
120 mM OG but not by 0.5 and 1% TX-100 treatments. Oligomer for-
mation of cav-2 was observed in the non-boiled and 60 mM
OG-treated non-boiled, consistent with the result shown in Fig. 3A,
b, samples but not detected in the boiled and 120 mM OG-treated
non-boiled samples (Fig. 3A, c). Thus, these results show that cav-2
without cav-1 is able to form large homo-oligomeric complexes in
the PM. Either MβCD treatment to deplete cholesterol from the PM
(70–85% depletion) or U18666A treatment from the Golgi complex
[41] (~50% depletion) did not affect the formation of cav-2 oligomeric
complexes (Fig. 3B).
As we explored structural feature of cav-2-localized microdomain
by analyzing isolated LDMV by shearing of silica-coated PM (Fig. 3C),
cav-2 was detected with cav-1 in the LDMV (fractions, 4–6) in the PM
of 3T3L1 cells having caveolae [42], and protected from the shearing
indicating that hetero-oligomerized cav-1/cav-2 formed invaginated
caveolae. When caveolae were disrupted by MβCD treatment, cav-2
was no longer detected with cav-1 in the LDMV fraction. In Hirc-B
and cav-2-expressed HEK293T cells lacking cav-1, cav-2 was also
protected from the shearing and detected in the LDMV but the
cav-2 in the LDMV was unaffected by MβCD treatment (Fig. 3C).
Being consistent with the observation from the electron microscope
image of Hirc-B cells exhibiting the absence of caveolae (Fig. 1C,
right panel), cav-2 did not interact with cavin-1 and cavin-2 known
as regulators of caveolae biogenesis [43] in the PM (Fig. 3D, a).
Confocal microscopy analysis also conﬁrmed that cavin-1-GFP or
cavin-2-GFP does not colocalize with cav-2 in the PM (Fig. 3D, b).
These results identify a noncaveolar microdomain composed of
homo-oligomerized cav-2 in the PM and show that the microdomain
has a unique structure that is protected from shearing of silica-coated
PM and distinct from cholesterol-dependent microdomain.
3.4. Actin cytoskeleton-dependent formation of homo-oligomeric cav-2
microdomain for insulin signaling activation via IR recruitment
To characterize cav-2-enriched noncaveolar microdomain in the
PM, a four-step sucrose density gradient fractionation was performed
to separate light low-density insoluble membrane (LLDM) and heavy
low-density insoluble membrane (HLDM) with puriﬁed PM. As
shown in Fig. 4A, ganglioside GM1 was enriched in the LLDM (frac-
tions, 1–4) and ﬂotillin-1 in the HLDM (fractions, 9–12) in control
as previously demonstrated [37,38]. Cav-2 was detected in the
HLDM and the localization was unchanged in response to insulin. IR
also localized in the HLDM where IR signaling was activated by insu-
lin stimulation (Fig. 4A, a and b). Cholesterol was enriched in the
HLDM of the PM and was depleted by MβCD treatment (Fig. 4A, c).
The colocalization of cav-2 and IR was refractory to the cholesterol
depletion and activation of IR, ERK and Akt was transduced in the
HLDM in response to insulin (Fig. 4A, d). These results show that IR
signaling is activated in the noncaveolar cav-2 and IR-colocalized
HLDM with no requirement of cholesterol.
Actin cytoskeleton participates in regulating lipid rafts-associated
signaling events [44–46]. To explore if actin cytoskeleton is involved
in localization of cav-2 and activation of IR signaling in the HLDM,
Hirc-B cells were treated with CCD or LatB. Depolymerization of
actin affected cav-2 localization in the HLDM and led to the detection
of cav-2 in the LLDM. And activation of IR signaling was not processed
in the HLDM although IR was detected in the HLDM (Fig. 4A, e and f).
To examine whether cav-2 regulates insulin signaling via IR recruit-
ment to the HLDM, IR protein level associated in the HLDM fraction
relative to that in whole cell lysate (WCL) was determined by resolv-
ing equal amounts of protein from WCL and LLDM and HLDM frac-
tions on SDS-PAGE and immunoblot analysis (Fig. 4B). Levels of
cav-2 and IR, and tyrosine phosphorylation of IR were elevated in
the HLDM fraction relative to WCL (Fig. 4B, lanes 1 vs. 3). And ERK
and Akt were also detected and activated in the HLDM. LatB
Fig. 2. PM targeting of cav-2 is blocked by Rab6 siRNA, dominant negative T27N-Rab6 mutant, and colchicine treatment. Hirc-B cells were transfected with cav-2-GFP and scramble
control or siRab6 (A), T27N-Rab6-mCherry (B), or treated with or without 10 μM colchicine for 3 h (C). PM sheets were prepared from the cells and stained with antibodies against
cav-2 and ﬂotillin-1. Colocalization of cav-2-GFP or cav-2 with ﬂotillin-1 in the PM sheets is shown in Merge and PDM values. (yellow, positive PDM; blue, negative PDM) Scale bars,
10 μm.
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lane 5) and reduced association and activation of IR, ERK, and Akt in
the HLDM (Fig. 4B, lanes 3 vs. 6). Consequently insulin-induced inter-
action between cav-2 and IR was attenuated and tyrosine kinase acti-
vation of IR were retarded (Fig. 4C). As we investigated effect of actin
cytoskeleton disruption on oligomeric status of cav-2, small oligo-
meric complexes of cav-2 (fractions, 2–4; low MW) were detected
in CCD or LatB-treated cells in contrast to large oligomeric complexes
of cav-2 found in control cells (Fig. 4D).To corroborate our ﬁndings a PM model system of GPMV was iso-
lated from Hirc-B cells and analyzed (Fig. 5). Cav-2-GFP did not
colocalize with CTB-Alexa Fluor® 594 conjugates (a LLDM marker)
(Fig. 5, Panel 1) while cav-2-mCherry coalesced with ﬂotillin-1-GFP
(a HLDM marker) (Fig. 5, panel 2) in the GPMV. MβCD treatment
did not alter coalescence of cav-2-mCherry with ﬂotillin-1-GFP
(Fig. 5, panel 3). Quantitative analysis conﬁrmed the colocalization
(%) of cav-2 with ﬂotillin-1 unaffected by cholesterol depletion. In op-
position to the results shown in Fig. 5, panels 1 and 2, cav-2-GFP
Fig. 3. Homo-oligomeric cav-2 noncaveolar microdomain in the PM is refractory to cholesterol depletion. (A) 3T3L1 (a) or Hirc-B (b) cells were lysed with lysis buffer containing
0.5, 1, and 2% TX-100 or 60 and 120 mM OG as indicated. Whole cell lysates (WCL) were run through 10–40% sucrose velocity gradients. An aliquot of each fraction was resolved by
SDS-PAGE and immunoblotted using antibodies against cav-1 and cav-2. (c) Hirc-B cells were lysed with lysis buffer with or without 60 or 120 mM OG. WCL were added with
SDS-PAGE loading buffer and boiled or incubated with SDS-PAGE loading buffer excluding β-mercaptoethanol at RT for 30 min and subjected to immunoblotting using antibody
against cav-2. (B) Hirc-B cells were treated with or without 10 mM MβCD for 2 h or 20 μg/ml U18666A for 24 h and lysed with lysis buffer containing 0.5% TX-100. WCL were
run through 10–40% sucrose velocity gradients. An aliquot of each fraction was resolved by SDS-PAGE and immunoblotted using antibody against cav-2. Cholesterol levels were
quantitated using a cholesterol assay kit (n = 3, mean ± S.E.). (C) Cells were treated with or without MβCD (3T3L1 and Hirc-B cells, 10 mM for 2 h; cav-2-transfected
HEK293T cells, 20 mM for 1 h) and subjected to PM isolation using silica-coating method. The silica-coated PM were sheared by sonication and subjected to sucrose density gra-
dient centrifugation. An aliquot of each fraction was resolved by SDS-PAGE and immunoblotted using antibodies against cav-2, cav-1, and ﬂotillin-1. (D) (a) FLAG-cav-2 and
cavin-1-GFP or cavin-2-GFP-cotransfected HEK293T cells were subjected to PM isolation. The puriﬁed PM were immunoprecipitated with anti-FLAG antibody and subjected to
immunoblot analysis with anti-GFP and anti-FLAG antibodies. (b) Cavin-1-GFP or cavin-2-GFP-transfected Hirc-B cells were labeled with anti-cav-2 antibody followed by
TRITC-conjugated antibody. Scale bars, 10 μm.
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while colocalization of cav-2-mCherry with ﬂotillin-1-GFP was abro-
gated in the GPMV (Fig. 5, panels 5 and 6) by actin ﬁlament disrup-
tion. Quantitative analysis veriﬁed inhibition in the colocalization
(%) of cav-2 with ﬂotillin-1 by CCD or LatB treatment. Taken together,
these data show that intact actin cytoskeleton is required for forma-
tion of large oligomeric complexes of cav-2 and sustenance of their
localization in the HLDM and suggest that homo-oligomeric cav-2 in
the PM facilitates IR recruiting and regulates insulin signaling cascade
thru activation of IR signaling by direct interaction between cav-2 and
IR.
3.5. Reconstitution of functional homo-oligomeric cav-2 microdomain in
the PM for IR signaling activation
To explore if absence of cav-2 in the HLDM leads to inhibition of IR
signaling activation, cav-2 shRNA stable Hirc-B cells were generated
(Fig. 6A). As shown in Fig. 6B, a, in the cav-2 shRNA stable cells,
insulin-induced tyrosine kinase activation of IR and phosphorylation
of ERK and Akt were not detected in the HLDM. However, ectopic ex-
pression of cav-2 restored cav-2 colocalization with IR in the HLDM
whereby IR signaling activation was processed in response to insulin
(Fig. 6B, b). When effect of cav-2 depletion on IR signaling activation
in total cellular level was assessed, cav-2 siRNA signiﬁcantly attenuat-
ed insulin-induced activation of IR, ERK, and Akt (Fig. 6C). These re-
sults show that cav-2-enriched microdomain in the PM speciﬁcally
regulates IR signaling activation. To test whether oligomeric status
is important to regulate IR signaling activation in the cav-2-enrichedmicrodomain, FLAG-cav-2Δ47–86, an oligomerization domain deletion
mutant expressing monomeric form of cav-2 (Fig. 6D) was ectopically
transfected. The mutant failed to localize to the PM and insulin signal-
ing activation was not processed in the HLDM in the FLAG-cav-2Δ47–
86-transfected cav-2 shRNA stable Hirc-B cells (Fig. 6E). To clarify if
the reconstitution of homo-oligomeric cav-2 microdomain in the
HLDM triggers IR recruitment to the microdomain, IR level in the
HLDM relative to WCL was analyzed in the cav-2 shRNA stable cells.
Control cells exhibited reduced IR and ERK and Akt levels in the
HLDM as compared to WCL and attenuation in activation of IR and
ERK and Akt in response to insulin (Fig. 6F, lanes 1 vs. 3). When
cav-2 was reexpressed, IR association with the HLDMwas dramatical-
ly elevated (Fig. 6F, lane 6) and insulin-induced activation of IR, ERK,
and Akt was processed (Fig. 6F, lanes 3 vs. 6). As shown in Fig. 6E,
cav-2Δ47–86 mutant was not detected in the HLDM and its
reexpression caused no effect on the IR recruiting and signaling acti-
vation in the HLDM (Fig. 6F, lane 9). Thus, these data show that
homo-oligomeric form of cav-2 is required for the regulation of IR sig-
naling activation in the HLDM.
3.6. IR signaling activation via reconstituted homo-oligomeric cav-2
noncaveolar microdomain by increasing status of cav-2 expression over
cav-1
In 3T3L1 cells having caveolae [42], cholesterol depletion (~80%
depletion) by MβCD treatment (Fig. 7A) prevented activation of insu-
lin signaling (Fig. 7, B and C). Whether expression of cav-2 enables to
activate IR signaling was tested in MβCD-treated 3T3L1 cells. The
Fig. 4. Actin cytoskeleton is required for sustenance of cav-2 localization and IR signaling activation in the HLDM. (A) Hirc-B cells were treated as follows; untreated control (a),
100 nM insulin for 10 min (b), 10 mM MβCD for 2 h prior to incubation with 100 nM insulin for 10 min (d), 1 μM CCD for 15 min prior to incubation with 100 nM insulin for
10 min (e), 1 μM LatB for 30 min prior to incubation with 100 nM insulin for 10 min (f). The cells were subjected to PM isolation. The puriﬁed PM were separated to LLDM and
HLDM using four-step sucrose density gradient fractionation. An aliquot of each fraction was resolved by SDS-PAGE and immunoblotted using antibodies against cav-2, IR, PY20,
p-ERK, and p-Akt. Each fraction was dot-blotted onto a nitrocellulose membrane to detect ganglioside GM1 with HRP-conjugated CTB. Ganglioside GM1 and ﬂotillin-1 are used
for markers for the LLDM and HLDM, respectively. (c) Cholesterol levels were quantitated from an aliquot of each fraction using a cholesterol assay kit. (B) Hirc-B cells were
pretreated with or without 1 μM LatB for 30 min followed by incubation with 100 nM insulin for 10 min and subjected to total cell lysis to yield WCL or PM isolation. The puriﬁed
PM were separated to LLDM and HLDM and fractions 1–4 were combined for LLDM and 9–12 for HLDM fractions. Protein was extracted from the fractions using TCA precipitation
and rehydration buffer (7 M urea, 2 M Thiolurea, 4% chaps, and 1 mM PMSF). Equal amounts of protein from WCL and LLDM and HLDM fractions were resolved by SDS-PAGE and
immunoblotted using antibodies against cav-2, IR, PY20, ERK, p-ERK, Akt, p-Akt, and ﬂotillin-1. The LLDM and HLDM fractions were dot-blotted onto a nitrocellulose membrane to
detect ganglioside GM1 with HRP-conjugated CTB (C) Cells were pretreated with or without 1 μM CCD for 15 min or 1 μM LatB for 30 min followed by incubation with or without
100 nM insulin for 10 min. WCL were immunoprecipitated with anti-IR antibody and subjected to immunoblotting with antibodies against cav-2, IR, and PY20. (D) Cells were treat-
ed with or without 1 μM CCD for 15 min or 1 μM LatB for 30 min and lysed with lysis buffer containing 0.5% TX-100. WCL were run through 10–40% sucrose velocity gradients. An
aliquot of each fraction was resolved by SDS-PAGE and immunoblotted using antibody against cav-2.
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Fig. 5. Colocalization of cav-2 with ﬂotillin-1 in the GPMVs is abrogated by disruption of actin cytoskeleton, but not depletion of cholesterol. Hirc-B cells were transfected with
cav-2-GFP or cotransfected with cav-2-mCherry and ﬂotillin-1-GFP. The cells were treated with or without 10 mM MβCD for 2 h, 1 μM CCD for 15 min, or 1 μM LatB for 30 min.
GPMVs were isolated from the cells and labeled with 2 μg/ml CTB-Alexa Fluor® 594 conjugates. The colocalization of cav-2-GFP with CTB-Alexa Fluor® 594 conjugates or
cav-2-mCherry with ﬂotillin-1-GFP was quantiﬁed by the Colocalization Finder Plugin of Image J (n = 3, mean ± S.E.). Scale bars, 5 μm.
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and decreased ~50% of cav-1 expression as compared to endogenous
cav-2 and cav-1 levels, respectively (Fig. 7B, lanes 1–4 vs. 5–8). The
reduction of cav-1 and elevation of cav-2 did not alter activation of
IR, ERK, and Akt in response to insulin (Fig. 7B, lanes 2 vs. 6). Howev-
er, insulin signaling retarded by MβCD treatment was restored by the
elevation of cav-2 expression (Fig. 7B, lanes 4 vs. 8). When effect of
cav-2 expression in cav-1-depleted cells was investigated, cav-1
siRNA decreased ~90% of cav-1 and ~70% of cav-2 protein levels
(Fig. 7C, lanes 1–4 vs. 5–8) and attenuated insulin-induced activation
of IR, ERK, and Akt (Fig. 7C, lanes 2 vs. 6). MβCD treatment-induced
retardation of insulin signaling was aggravated by cav-1 down-
regulation (Fig. 7C, lanes 4 vs. 8). Subsequent transfection of cav-2 re-
storing cav-2 status to the levels of scramble controls and abolishingcav-1 expression (Fig. 7C, lanes 5–8 vs. 9–12) resulted in activation
of insulin signaling (Fig. 7C, lanes 6 vs. 10) that was not affected by
cholesterol depletion (Fig. 7C, lanes 10 vs. 12). Finally, we investigat-
ed if ectopic cav-2 leads to formation of PM noncaveolar
microdomain composed of homo-oligomeric cav-2 for IR signaling ac-
tivation in 3T3L1 cells. As shown in Fig. 7D, a, endogenous cav-2
colocalized with cav-1 in the HLDM where IR signaling was activated
in response to insulin. Cav-1 depletion causing disruption of caveolae
led to inhibition of IR signaling activation. Consistent with the results
shown in Fig. 7C, cav-1 depletion caused signiﬁcant reduction of
cav-2 expression (Fig. 7D, b). Upon subsequent expression of ectopic
cav-2, the cav-2 colocalized with IR and activation of insulin signaling
was restored in the HLDM in response to insulin (Fig. 7D, c). As the ef-
fect of ectopic cav-2 expression on IR recruitment to the HLDM was
Fig. 6. Formation of functional homo-oligomeric cav-2 in the HLDM is necessary for IR signaling activation. (A) A stable Hirc-B cell line that expresses a cav-2 shRNA (#1 or #2) was
generated. The effect of the shRNA on the protein expression of cav-2 is shown by immunoblot analysis. (B) Cav-2 shRNA (#2) stable (a) and FLAG-cav-2-expressed cav-2 shRNA stable
(b) Hirc-B cells were treated with 100 nM insulin for 10 min and subjected to PM isolation. The puriﬁed PM were separated to LLDM and HLDM and analyzed as in Fig. 4A. (C) Hirc-B
cells were transfected with scramble control or cav-2 siRNA and treated with or without 100 nM insulin for 10 min. WCL were subjected to immunoblotting using antibodies against
PY20, IR, p-ERK, ERK, p-Akt, Akt, cav-2, and actin. (D) Hirc-B cells were transfected with FLAG-cav-2 or FLAG-cav-2Δ47–86. WCL were incubated with SDS-PAGE loading buffer excluding
β-mercaptoethanol at RT for 30 min and subjected to immunoblotting using antibody against FLAG. (E) FLAG-cav-2Δ47–86-expressed cav-2 shRNA stable Hirc-B cells were treated with
100 nM insulin for 10 min and subjected to PM isolation. The puriﬁed PM were separated to LLDM and HLDM and analyzed as in Fig. 4A. (F) Cav-2 shRNA stable and FLAG-cav-2 or
FLAG-cav-2Δ47–86–expressed cav-2 shRNA stable Hirc-B cells were treated with 100 nM insulin for 10 min and subjected to total cell lysis to yield WCL or PM isolation. The puriﬁed
PM were separated to LLDM and HLDM and analyzed as in Fig. 4B.
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in cav-1-depleted cells as compared to scramble control (Fig. 7E,
lanes 3 vs. 6) while cav-2 level was decreased in the HLDM and the
WCL as shown in Fig. 7C, lanes 5–8 (Fig. 7E, lanes 1 and 3 vs. 4 and
6). Expression of ectopic cav-2 in the cav-1-depleted cells (Fig. 7E,
lanes 4 and 6 vs. 7 and 9) elevated IR, ERK and Akt association in
the HLDM (Fig. 7E, lanes 6 vs. 9) and restored insulin-induced
tyrosine phosphorylation of IR and activation of ERK and Akt in the
HLDM (Fig. 7E, lanes 6 vs. 9). These results demonstrate that IR
signaling is transduced via homo-oligomeric cav-2 noncaveolar
microdomain in the PM, which is reconstituted by increasing status
of cav-2 expression over cav-1.
4. Discussion
IR is localized to and signals via caveolae in adipocytes [47].
Interaction between IR and cav-1 in caveolae leads to an increase in
tyrosine kinase activity of IR [48,49]. In liver-derived cells lacking
caveolae, however, IR signaling cascade is initiated in noncaveolar
raft domains indicating that caveolae and cav-1 is not necessarily
required for insulin signaling [50]. Our previous works showed thatcav-2 interacts with IR and regulates IR signaling activation in cells
lacking cav-1 [21,23]. However, the underlying mechanism for regu-
lation of insulin signaling via the interaction between cav-2 and IR
in the PM has not been investigated.
Previous reports showed that cav-2 mainly localized in the Golgi in
cells lacking cav-1 and cav-1 expression was required for transport of
cav-2 to caveolae in the PM [14,15,18,25–27]. Our recent study also
demonstrated that cav-2 exclusively colocalized with GM130 in
Hirc-B and HEK293T cells lacking cav-1. But we could not detect PM lo-
calization and targeting of cav-2 by ﬂuorescence microscopy even after
ectopic expression of cav-1 in the cells, although subcellular fraction-
ation data showed cav-2 localization in the PM [28]. In the present
study, cav-2 localization in the PM is demonstrated by confocal immu-
noﬂuorescence and immunoelectron microscopy (Fig. 1, A, C and D).
Further, the PM localization of cav-2 independently of cav-1 is con-
ﬁrmed by a number of independent analyses including subcellular
and LDMV fractionation, cell surface biotinylation and PM sheet
assays, and GPMV and ectopic reconstitution. Our observation in
contrast to the others raises one possibility that cell-type dependent na-
ture could potentially contribute to the different intracellular localiza-
tion of cav-2. Another possibility would be the technical difﬁculty to
Fig. 7. Elevation of cav-2 expression status relative to cav-1 restores activation of insulin signaling in cholesterol- or/and cav-1-depleted cells. (A) 3T3L1 cells were treated with or
without 10 mM MβCD for 2 h. Cholesterol levels were measured by a cholesterol assay kit in the treated cells (n = 3, mean ± S.E.). (B and C) 3T3L1 cells were transfected with
vector or cav-2 (B), or scramble control, cav-1 siRNA, or cav-1 siRNA and cav-2 (C), and pretreated with or without 10 mM MβCD for 2 h, followed by incubation with or without
100 nM insulin for 10 min. WCL were subjected to immunoblotting using antibodies against PY20, IR, p-ERK, ERK, p-Akt, Akt, cav-2, cav-1, and actin. (D and E) 3T3L1 cells
transfected with scramble control (a), cav-1 siRNA (b), or cav-1 siRNA and cav-2 (c) were treated with 100 nM insulin for 10 min and subjected to total cell lysis to yield WCL
or PM isolation. The puriﬁed PM were separated to LLDM and HLDM and analyzed as in Fig. 4A (D) or Fig. 4B (E).
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cav-2 pool in the PM, depending on different cell types because the
cav-2-enriched noncaveolar PMmicrodomains are smaller and dynam-
ic as compared to caveolaewhich are larger (~200 nm in diameter) and
stable structure and can be easily detected by ﬂuorescence and electron
microscopy. Although our ﬁndings are restricted to three cell types(Hirc-B, HEK293T and 3T3L1 cells), the results suggest that even in
the cells constitutively form caveolae in association with cavins in
the PM, cav-2 translocates to the PM independently of cav-1 and
forms actin cytoskeleton-dependent homooligomerized noncaveolar
microdomain with no interaction with cavins in the PM, which is
refractory to cholesterol depletion. Further, our ﬁndings suggest that
2188 H. Kwon et al. / Biochimica et Biophysica Acta 1833 (2013) 2176–2189cav-2 localizes in the PM and acts as the major independent functional
component for the noncaveolar microdomain or/and as a structural
component, as generally described, associated with cav-1 in caveolae,
depending on speciﬁc cell types.
The present data provide insight into the molecular mechanism
responsible for PM targeting of cav-2 in the absence of cav-1. A
small GTPase Rab6 regulates exocytic transport by enhancing kinesin,
a microtubule-dependent motor protein-driven movement of secre-
tory vesicle from the Golgi [40]. We have shown that cav-2 speciﬁcal-
ly interacts with Rab6, but not Rab5 and Rab1 [28]. When the cells
lacking cav-1, in which cav-2 localizes in the Golgi and PM (Fig. 1)
were transfected with Rab6 siRNA or GDP-bound form of Rab6, or
treated with colchicine, cav-2 targeting to the PM was greatly retard-
ed (Fig. 2). Thus the present data reveal that Rab6 regulates
microtubule-dependent exocytic transport of cav-2 from the Golgi
to the PM independently of cav-1.
The present study shows that a functional cav-2-enriched
microdomain is present in the PM for insulin signaling. The novel
noncaveolar microdomain is composed of homo-oligomeric cav-2, in
which IR localizes and its tyrosine kinase activation and phosphorylation
of ERK and Akt are processed in response to insulin. Of interest, IR sig-
naling activation in the microdomain was unaffected by perturbation
of cholesterol (Fig. 4) and by depletion of ganglioside (Supplementary
Fig. 1) or sphingomyelin (Supplementary Fig. 2). However, actin cyto-
skeleton disruption caused dissipation of cav-2 in the microdomain
resulting in no IR recruitment to the microdomain thereby restraining
IR activation (Fig. 4). Further actin cytoskeleton-dependent mainte-
nance of large oligomeric form of cav-2 in the microdomain was crucial
for cav-2 interaction with IR and subsequent activation of insulin signal-
ing (Figs. 4 and 6). Together, the present data show that a novel
cav-2-oligomerized microdomain, which serves as a platform for IR to
regulate insulin signaling cascade, exists depending on intact actin cyto-
skeleton and is distinct from caveolae and cholesterol/sphingolipid-
enriched microdomain in the PM.
Actin cytoskeleton disruption facilitated rapid caveolar endocyto-
sis [51,52]. The present data show that depolymerization of actin
caused cav-2 depletion in the HLDM and its relocalization in the
LLDM in the form of small oligomeric complexes. However no signif-
icant reduction of cav-2 level in the LLDMwas detected, indicating no
facilitative endocytosis of cav-2 (Fig. 4). Our ongoing investigation on
the cav-2 endocytosis by using subcellular fractionation has shown
that cav-2 in the PM pool is gradually decreased in response to insulin
in a time-dependent manner. Although these results suggest that
cav-2 internalization occurs in the PM, further work is necessary to
identify the precise mechanism for cav-2 endocytosis and actin de-
pendency on oligomerization status of cav-2 in the PM.
When structural feature of cav-2-oligomerized microdomain was
assessed by fractionating LDMVs which contain invaginated caveolae
protected from shearing of silica-coated PMs (Fig. 3C), cav-2 was
detected in the LDMV of 3T3L1 cells having caveolae. Upon MβCD
treatment, cav-2 was no longer protected from the shearing, appar-
ently resulted from caveolae disruption. Interestingly, cav-2 was
found in the LDMV in cells having no cav-1 and caveolae and cav-2
cofractionated in the LDMV was unaffected by MβCD treatment.
These results suggest that cav-2-oligomerized microdomain in
the PM exists in a morphologically protected structure against silica
shearing of the PM or that a novel caveolae consisted of homo-
oligomeric cav-2 is present in the PM. However, electron microscopic
analysis showed no morphologically detectable caveolae (Fig. 1C,
right panel). Further, cav-2 did not interact with cavin-1 and
cavin-2 which are required for caveolae biogenesis [42] in the PM
(Fig. 3D). Together, these data suggest that a novel noncaveolar
microdomain composed of homo-oligomeric cav-2 with neutral
lipids, which are unable to ionic interact with cationic silica exists in
the topology of planar shape in the PM and is distinct from the
morphologically invaginated omega shape caveolae.Cav-1-deﬁcient mice showed ~95% reduction of cav-2 protein
level and defective IR signaling in adipose tissue [53]. Cav-2-
deﬁcient mice exhibited a mild reduction of cav-1 expression and
cav-1 localization in caveolae with no change in IR protein level
[17,53], suggesting that IR signaling could be processed in caveolae.
The present data show that elevation of cav-2 expression promotes
IR signaling despite reduction of cav-1 protein level and induces the
noncaveolar activation of insulin signaling in caveolae-deﬁcient cells
(Fig. 7). Thus, our ﬁndings provide a molecular mechanism for
regulation of insulin signaling by formation and maintenance of
cav-2-enriched noncaveolar microdomain in the PM by modulating
status of caveolin expression. It will be interesting to test if defective
IR signaling observed in the cav-1-deﬁcient mice can be rescued by
increasing status of cav-2 expression.
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